Legend Biotech (NASDAQ:LEGN) Given New $62.00 Price Target at Royal Bank Of Canada

Legend Biotech (NASDAQ:LEGN) had its target price decreased by Royal Bank Of Canada from $66.00 to $62.00 in a research report sent to investors on Wednesday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

LEGN has been the subject of a number of other reports. Cantor Fitzgerald reduced their target price on shares of Legend Biotech from $75.00 to $74.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Morgan Stanley dropped their price objective on shares of Legend Biotech from $83.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Legend Biotech in a report on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and set a $69.00 target price on shares of Legend Biotech in a report on Tuesday. Finally, Rothschild & Co Redburn lowered Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 price target for the company. in a research report on Thursday, February 12th. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $58.31.

Legend Biotech Price Performance

NASDAQ:LEGN opened at $20.27 on Wednesday. The firm’s fifty day moving average is $19.48 and its two-hundred day moving average is $26.43. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -25.34 and a beta of 0.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.80 and a current ratio of 2.86. Legend Biotech has a one year low of $16.24 and a one year high of $45.30.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Tuesday, March 10th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.18. Legend Biotech had a negative return on equity of 21.83% and a negative net margin of 28.86%.The firm had revenue of $306.30 million for the quarter, compared to analyst estimates of $310.21 million. During the same period in the previous year, the company posted $0.07 earnings per share. The business’s revenue was up 64.2% on a year-over-year basis. Research analysts expect that Legend Biotech will post -1.31 EPS for the current year.

Hedge Funds Weigh In On Legend Biotech

Several institutional investors and hedge funds have recently bought and sold shares of the company. Suvretta Capital Management LLC grew its stake in shares of Legend Biotech by 73.1% in the 4th quarter. Suvretta Capital Management LLC now owns 6,608,629 shares of the company’s stock valued at $143,672,000 after buying an additional 2,790,620 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Legend Biotech by 120.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,174,535 shares of the company’s stock valued at $47,274,000 after acquiring an additional 1,188,449 shares during the last quarter. Davern Capital Partners LP purchased a new position in Legend Biotech in the fourth quarter worth approximately $22,972,000. Artisan Partners Limited Partnership increased its stake in Legend Biotech by 87.5% during the second quarter. Artisan Partners Limited Partnership now owns 2,122,268 shares of the company’s stock worth $75,319,000 after acquiring an additional 990,500 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Legend Biotech by 4,129.8% during the fourth quarter. Marshall Wace LLP now owns 755,953 shares of the company’s stock worth $16,434,000 after acquiring an additional 738,081 shares during the last quarter. 70.89% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Legend Biotech

Here are the key news stories impacting Legend Biotech this week:

• Positive Sentiment: Q4 report showed continued commercial traction: CARVYKTI revenue jumped sharply (reported as a ~66% increase) and management reiterated a 2026 profit target, which supports upside to future earnings and valuation. Legend Biotech (LEGN) Stock: CARVYKTI Revenue Soars 66% in Q4 with 2026 Profit Target
• Positive Sentiment: Company released Q4 and full‑year 2025 results showing a YoY revenue jump (~64%) and an EPS beat vs. consensus, signaling improving top‑line momentum and progress toward profitability. Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
• Positive Sentiment: Morgan Stanley kept an overweight rating (PT trimmed from $50 to $49), signaling continued analyst conviction in upside potential despite the small cut. Benzinga
• Positive Sentiment: RBC left an outperform rating (PT lowered from $66 to $62), another buy‑side endorsement that supports investor optimism about long‑term growth. Benzinga
• Neutral Sentiment: Full earnings call transcript and slide deck are available for detailed read‑throughs of guidance, margin outlook, and commercial cadence — useful for modeling but neutral until new guidance or surprises emerge. Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Company presentation from the Q4 call summarizes results and strategic priorities (useful for modeling uptake and margin trajectory). Legend Biotech Corporation 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: Revenue missed consensus by a few million ($306.3M vs. ~$310M est.) and the company still reports negative net margins/return on equity, indicating profitability progress remains incomplete and leaving headline risk if future quarters disappoint. MarketBeat earnings summary

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.